Trial design for a phase 3 study evaluating pemigatinib (INCB054828) versus gemcitabine plus cisplatin chemotherapy in first-line treatment of patients with cholangiocarcinoma with FGFR2 rearrangement
Bekaii-Saab, TS Valle, Juan W Borad, MJ Melisi, D Vogel, A Feliz, L Lihou, CF Zhen, HL Abou-Alfa, GK
Bekaii-Saab, TS
Valle, Juan W
Borad, MJ
Melisi, D
Vogel, A
Feliz, L
Lihou, CF
Zhen, HL
Abou-Alfa, GK
Citations
Altmetric:
Abstract
Affiliation
Mayo Clinic, Phoenix, AZ
Description
Date
2019
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Bekaii-Saab TS, Valle JW, Borad MJ, Melisi D, Vogel A, F�liz L, et al. Trial design for a phase 3 study evaluating pemigatinib (INCB054828) versus gemcitabine plus cisplatin chemotherapy in first-line treatment of patients with cholangiocarcinoma with FGFR2 rearrangement. J Clin Oncol. 2019;37(4_suppl):TPS462-TPS.